secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001601485-24-000067
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio reports ELI-002 Phase 1 data: T cell responses correlate with DFS; Phase 2 enrollment expected Q4 2024
--------------------------------------------------------------------------------

- All 12 evaluable patients showed mKRAS-specific T cell responses; RP2D group had 12-fold higher median response vs 1.4 mg group.
- T cell response magnitude correlated with DFS: lowest quartile mDFS 3.1 months (p=0.0027), top three quartiles not yet reached.
- Antigen spreading in 100% of RP2D-treated patients (n=6); T cells targeted 67.5% of patient-specific neoantigens.
- ELI-002 remains safe and well-tolerated; no dose-limiting toxicities or cytokine release syndrome observed.
- Phase 2 enrollment expected to complete in Q4 2024; interim event-driven DFS analysis expected H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000067/0001601485-24-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000067/angn-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001601485-24-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer